The DOI matches its Crossref record.
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Knowing CIP2A status in recurrent ovarian tumors may help predict clinical response to APR-246.
“These results indicate that diagnostic identification of CIP2A status in recurrent OvCa tumors could have predictive potential for these patients regarding clinical responsiveness to APR-246 currently in clinical development (22,23).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [23]
APR-246 has been studied in a clinical trial in ovarian cancer and showed promising clinical activity in a recent phase II trial in acute myeloid leukemia.
“APR-246 (Eprenetapopt) has been studied in clinical trial in OvCa (19), and it showed promising clinical activity in a recent phase II trial in acute myeloid leukemia (AML) (18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [19]
Diagnostic identification of CIP2A low status in human recurrent ovarian cancer tumors could have predictive potential for these patients regarding clinical responsiveness to APR-246.
“These results indicate that diagnostic identification of CIP2A low status in human recurrent OvCa tumors could have predictive potential for these patients regarding clinical responsiveness to APR-246 currently in clinical development (18,19).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0622 · Cited by 5
Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5
Metadata
- Authors
- Basu, B., Gourley, C., Gabra, H., Vergote, I. B., Brenton, J. D., Abrahmsen, L., Smith, A., Von Euler, M., & Green, J. A.
- Affiliations
- University of Cambridge (GB)
- Institute of Genetics and Cancer (GB)
- Hammersmith Hospital (GB)
- Universitair Ziekenhuis Leuven (BE)
- OncoGenex Pharmaceuticals (United States) (US)
- University of Liverpool (GB)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 27
- Pages
- vi123
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2587854885
- Cited by
- 8
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- APR-246, carboplatin, pegylated liposomal doxorubicin, TP53 mutation, glutathione depletion, thioredoxin reductase inhibition, recommended phase 2 dose, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
